Despite advances in our understanding of the genetic, immunologic and environmental factors that contribute to the etiopathogenesis of ulcerative colitis, there is still no pathognomonic marker ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...

Approximately 15% of patients with ulcerative colitis develop an acute attack of severe colitis, and 30% of these patients require colectomy. Severe ulcerative colitis is therefore considered a ...

With over 250 peer-reviewed publications, he has made significant contributions to medical literature, shedding light on the treatment and understanding of ulcerative colitis and Crohn's disease.

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Ulcerative colitis is an inflammatory bowel disease that is characterized by chronic inflammation of the colon. The direct cause of the disease is unknown, but patients are commonly treated with ...

[5] After exclusions of such diseases as infectious colitis, bacillary dysentery, amebiasis, chronic schistosomiasis, intestinal tuberculosis, Crohn's disease, ischemic colitis and radiation ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.

"There is a pressing need to modernize traditional endoscopic assessments in IBD to enhance precision and efficiency in ulcerative colitis research," said Mark Genovese, MD, Senior Vice President of ...

Over a 3-year period, MACE occurred in 10.3% of patients taking ustekinumab and 12.2% of patients taking vedolizumab for those with ulcerative colitis (adjusted HR 0.88, 95% CI 0.74-1.05), and in ...